DOCSLIB.ORG

Orbitomaxillary Mucormycosis (Zygomycosis) and the Surgical Approach to Treatment: Perspectives from a Maxillofacial Surgeon

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Orbitomaxillary Mucormycosis (Zygomycosis) and the Surgical Approach to Treatment: Perspectives from a Maxillofacial Surgeon View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW 10.1111/j.1469-0691.2009.02989.x Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon A. D. Rapidis Department of Maxillofacial Surgery, Greek Anticancer Institute, St. Savvas Hospital, Athens, Greece Abstract Rhinocerebral or rhino-orbitocerebral (mucormycosis) zygomycosis (ROCZ) usually occurs among patients with poorly controlled diabetes mellitus (especially those with ketoacidosis), solid malignancies, iron overload or extensive burns, in patients undergoing treat- ment with glucocorticosteroid agents, or in patients with neutropenia related to haematologic malignancies. The disease process starts with inhalation of the fungus into the paranasal sinuses. The fungus may spread to invade the palate, sphenoid sinus, cavernous sinus, orbits or cranially to invade the brain. Pain and swelling precede oral ulceration and the resulting tissue necrosis can result in palatal perforation. Infection can sometimes extend from the sinuses into the mouth and produce painful, necrotic ulcerations of the hard palate. If untreated, infection usually spreads from the ethmoid sinus to the orbit, resulting in the loss of extraocular muscle function and proptosis. Surgical treatment includes the resection of involved tissues of the face, including skin and muscle, any skin of the nose that is involved, maxillary and ethmoid sinuses, necrotic tissue of the temporal area and infratemporal fossa, and orbital exenteration. The keys to successful therapy include suspicion of the diagnosis and early recognition of the signs and symptoms, correction of under- lying medical disorders such as ketoacidosis, and aggressive medical and surgical intervention. Keywords: Maxillectomy, mucormycosis, orbital exenteration, zygomycosis Clin Microbiol Infect 2009; 15 (Suppl. 5): 98–102 ity of cases reported have represented either isolated Corresponding author and reprint requests: A. D. Rapidis, examples or small, retrospective series. This relative scarcity Department of Maxillofacial Surgery, Greek Anticancer Institute, St. Savvas Hospital, 171 Alexandras Avenue, Athens 115 22, Greece of cases hinders the drawing of diagnostic and therapeutic E-mail: [email protected] conclusions [4]. However, with the increasing prevalence of diabetes and immunosuppressive conditions, mucormycosis has emerged as an important fungal infection. Based on clini- cal presentation and the involvement of a particular anatomic Introduction site, mucormycosis can be divided into at least six clinical categories: (i) rhinocerebral; (ii) pulmonary; (iii) cutaneous; Zygomycetes have a wide geographical distribution, are all (iv) gastrointestinal; (v) disseminated, and (iv) miscellaneous thermo-tolerant, and utilize a variety of nutritional sub- [5,6]. strates. In nature, they are found in the soil, animal faeces and decaying plant materials [1,2]. They spread by the pro- Risk Factors and Pathophysiology of duction of sporangiospores that are released into the envi- Rhinocerebral or Rhino-orbitocerebral ronment as airborne propagules. Humans are usually Zygomycosis resistant to the disease because Mucorales fungi are ubiqui- tous in the environment. Nosocomial infections can occur from sporangiospores released through contaminated air- Rhinocerebral or rhino-orbitocerebral zygomycosis (ROCZ) conditioning systems or contaminated wound dressings. The usually occurs among patients with poorly controlled diabe- fungus exhibits a remarkable affinity for arteries and grows tes mellitus (especially those with ketoacidosis), solid malig- along the internal elastic lamina, causing thrombosis and nancies, iron overload or extensive burns, or in patients who infarction. Infections occur equally in both sexes, irrespective take glucocorticosteroid agents or have neutropenia related of age. to haematologic malignancies. A recently identified important Mucormycosis, also known as zygomycosis and phycomy- clinical feature is the increased susceptibility to mucormyco- cosis, was first described by Paultauf in 1885 [3]. The major- sis of patients with elevated available serum iron. It has been ª2009 The Author Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases CMI Rapidis Surgical approaches to orbitomaxillary mucormycosis 99 known for two decades that patients treated with the iron media. This direct invasion and dissection by the fungus chelator deferoxamine have a markedly increased incidence causes extensive endothelial damage, resulting in thrombus of invasive mucormycosis [7, 8]. However, it is now clear formation and ischaemia to the surrounding tissues. The that iron chelation is not the mechanism by which deferox- infarcted tissue creates an environment that promotes fungal amine enables mucormycosis infections. Although deferox- proliferation and the resultant poor vascular supply prevents amine is an iron chelator from the perspective of the human systemic medical therapy from eradicating the fungus. The host, Rhizopus spp. actually utilize deferoxamine as a sidero- nasal and sinus walls are invaded via these vessels and the phore to supply previously unavailable iron to the fungus. orbit is invaded secondarily via freely communicating fora- Patients with diabetic ketoacidosis are at high risk of devel- men and venous channels. The fungus invades the cranium oping rhinocerebral mucormycosis. Multiple lines of evidence through either the orbital apex or the cribriform plate of the support the conclusion that patients with systemic acidosis ethmoids and ultimately kills its host [14,15]. have elevated levels of available serum iron, probably as a result of the release of iron from binding proteins in the Clinical Symptoms and Signs presence of acidosis [9]. Neutropenia is another significant risk factor. The correction of neutropenia with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage The initial symptoms of ROCZ are consistent with either colony-stimulating factor (GM-CSF) is important to improve sinusitis or periorbital cellulitis and include eye or facial outcome. A breakthrough in the management of zygomycosis pain and facial numbness, followed by the onset of conjunc- in patients with neutropenia was recently achieved with tival suffusion, blurry vision and soft tissue swelling. Symp- empirical voriconazole therapy in the absence of ampho- toms that may suggest mucormycosis in susceptible tericin B (AmB) [10,11]. Initiation of early and appropriate individuals include multiple cranial nerve palsies, unilateral antifungal administration and, if required, discontinuation of periorbital facial pain, orbital inflammation, eyelid oedema, steroids or deferoxamine is advisable [12]. blepharoptosis, proptosis, acute ocular motility changes, Rhinocerebral mucormycosis continues to be the most internal or external ophthalmoplegia, headache or acute common form of the disease, accounting for between one- vision loss. Fever is variable and may be absent in up to third and one-half of all cases of mucormycosis. Approxi- half of the cases. White blood cell counts are typically ele- mately 70% of rhinocerebral cases (occasionally referred to vated, as long as the patient has functioning bone marrow as craniofacial cases) occur in diabetes patients with keto- [16,17]. acidosis. More rarely, rhinocerebral mucormycosis has also Upon visual inspection, infected tissue may appear normal occurred in patients who have received a solid organ trans- during the earliest stages of spread of the fungus. Infected plant or those with prolonged neutropenia. Recently, rhino- tissue then progresses through an erythematous phase, with cerebral disease has become an increasing problem in or without oedema, before the onset of a violaceous appear- patients undergoing haematopoietic stem cell transplantation. ance and, finally, the development of a black, necrotic eschar These cases have largely been associated with steroid use as the blood vessels become thrombosed and tissue infarc- for graft vs. host disease [13]. tion occurs. Palatal involvement is usually the result of the Infection with Zygomycetes can be acquired by inhalation, direct extension of disease from the maxillary sinus and in ingestion or the deposition of spores in wounds. The fungi the distribution of the sphenopalatine and greater palatine give rise to pathogenic lesions as a result of invasion and arteries. Pain and swelling precede oral ulceration, and the growth within the lumen and walls of major blood vessels, resulting tissue necrosis can result in palatal perforation. with ensuing thromboembolism resulting in ischaemia and tis- Infection can sometimes extend from the sinuses into the sue necrosis. Agents of zygomycosis have a predilection for mouth and produce painful, necrotic ulcerations of the hard the internal elastic lamina of the arterial blood vessels and palate. If untreated, infection usually spreads from the eth- spread by angioinvasion. The disease process in the ROCZ moid sinus to the orbit, resulting in loss of extraocular mus- form probably starts with the inhalation of the fungus into cle function and proptosis. Marked chemosis may also be the paranasal sinuses. Upon germination, the fungus may seen. The infection may rapidly extend into the neighbouring spread inferiorly to invade the palate, posteriorly to invade tissues [18]. the sphenoid sinus and beyond into the cavernous
Load more

Recommended publications
  • Estimated Burden of Fungal Infections in Oman
    Journal of Fungi Article Estimated Burden of Fungal Infections in Oman Abdullah M. S. Al-Hatmi 1,2,3,* , Mohammed A. Al-Shuhoumi 4 and David W. Denning 5 1 Department of microbiology, Natural & Medical Sciences Research Center, University of Nizwa, Nizwa 616, Oman 2 Department of microbiology, Centre of Expertise in Mycology Radboudumc/CWZ, 6500 Nijmegen, The Netherlands 3 Foundation of Atlas of Clinical Fungi, 1214GP Hilversum, The Netherlands 4 Ibri Hospital, Ministry of Health, Ibri 115, Oman; [email protected] 5 Manchester Fungal Infection Group, Manchester Academic Health Science Centre, The University of Manchester, Manchester M13 9PL, UK; [email protected] * Correspondence: [email protected]; Tel.: +968-25446328; Fax: +968-25446612 Abstract: For many years, fungi have emerged as significant and frequent opportunistic pathogens and nosocomial infections in many different populations at risk. Fungal infections include disease that varies from superficial to disseminated infections which are often fatal. No fungal disease is reportable in Oman. Many cases are admitted with underlying pathology, and fungal infection is often not documented. The burden of fungal infections in Oman is still unknown. Using disease frequencies from heterogeneous and robust data sources, we provide an estimation of the incidence and prevalence of Oman’s fungal diseases. An estimated 79,520 people in Oman are affected by a serious fungal infection each year, 1.7% of the population, not including fungal skin infections, chronic fungal rhinosinusitis or otitis externa. These figures are dominated by vaginal candidiasis, followed by allergic respiratory disease (fungal asthma). An estimated 244 patients develop invasive aspergillosis and at least 230 candidemia annually (5.4 and 5.0 per 100,000).
    [Show full text]
  • Mucormycosis of the Central Nervous System
    Journal of Fungi Review Mucormycosis of the Central Nervous System 1 1,2, , 3, , Amanda Chikley , Ronen Ben-Ami * y and Dimitrios P Kontoyiannis * y 1 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 64239, Israel 3 Department of Infectious Diseases, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA * Correspondence: [email protected] (R.B.-A.); [email protected] (D.P.K.) These authors contribute equally to this paper. y Received: 6 June 2019; Accepted: 7 July 2019; Published: 8 July 2019 Abstract: Mucormycosis involves the central nervous system by direct extension from infected paranasal sinuses or hematogenous dissemination from the lungs. Incidence rates of this rare disease seem to be rising, with a shift from the rhino-orbital-cerebral syndrome typical of patients with diabetes mellitus and ketoacidosis, to disseminated disease in patients with hematological malignancies. We present our current understanding of the pathobiology, clinical features, and diagnostic and treatment strategies of cerebral mucormycosis. Despite advances in imaging and the availability of novel drugs, cerebral mucormycosis continues to be associated with high rates of death and disability. Emerging molecular diagnostics, advances in experimental systems and the establishment of large patient registries are key components of ongoing efforts to provide a timely diagnosis and effective treatment to patients with cerebral mucormycosis. Keywords: central nervous system; mucormycosis; Mucorales; zygomycosis 1. Introduction Mucormycosis is the second most frequent invasive mold disease after aspergillosis [1–3], with rising incidence reported in some countries [4–7].
    [Show full text]
  • Epidemiological Alert: COVID-19 Associated Mucormycosis
    Epidemiological Alert: COVID-19 associated Mucormycosis 11 June 2021 Given the potential increase in cases of COVID-19 associated mucormycosis (CAM) in the Region of the Americas, the Pan American Health Organization / World Health Organization (PAHO/WHO) recommends that Member States prepare health services in order to minimize morbidity and mortality due to CAM. Introduction In recent months, an increase in reports of cases of Mucormycosis (previously called zygomycosis) is the term used to name invasive fungal infections (IFI) COVID-19 associated Mucormycosis (CAM) has caused by saprophytic environmental fungi, been observed mainly in people with underlying belonging to the subphylum Mucoromycotina, order diseases, such as diabetes mellitus (DM), diabetic Mucorales. Among the most frequent genera are ketoacidosis, or on steroids. In these patients, the Rhizopus and Mucor; and less frequently Lichtheimia, most frequent clinical manifestation is rhino-orbital Saksenaea, Rhizomucor, Apophysomyces, and Cunninghamela (Nucci M, Engelhardt M, Hamed K. mucormycosis, followed by rhino-orbital-cerebral Mucormycosis in South America: A review of 143 mucormycosis, which present as secondary reported cases. Mycoses. 2019 Sep;62(9):730-738. doi: infections and occur after SARS CoV-2 infection. 1,2 10.1111/myc.12958. Epub 2019 Jul 11. PMID: 31192488; PMCID: PMC6852100). Globally, the highest number of cases has been The infection is acquired by the implantation of the reported in India, where it is estimated that there spores of the fungus in the oral, nasal, and are more than 4,000 people with CAM.3 conjunctival mucosa, by inhalation, or by ingestion of contaminated food, since they quickly colonize foods rich in simple carbohydrates.
    [Show full text]
  • An Aggressive Case of Mucormycosis
    Open Access Case Report DOI: 10.7759/cureus.9610 An Aggressive Case of Mucormycosis Donovan Tran 1 , Berndt Schmit 2 1. Diagnostic Radiology, University of Arizona College of Medicine - Tucson, Tucson, USA 2. Radiology, University of Arizona College of Medicine - Tucson, Tucson, USA Corresponding author: Donovan Tran, [email protected] Abstract Mucormycosis is an aggressive fungal disease that can occur in individuals with certain predisposing factors, such as diabetes mellitus and pharmacologic immunosuppression. An astounding aspect of this disease is the speed at which it can spread to surrounding structures once it begins to germinate inside the human body. This case involves a 24-year-old male patient who presented to the emergency room complaining of a headache after a dental procedure who developed fulminant rhinocerebral mucormycosis within days. The objective of this report is to shed light on how fast this disease spreads, discuss current management of rhinocerebral mucormycosis, and illustrate the subtle, but critical radiographic findings to raise clinical awareness for this life-threatening disease. Categories: Emergency Medicine, Radiology, Infectious Disease Keywords: rhinocerebral mucormycosis, mucormycosis, rhizopus, invasive fungal sinusitis, retroantral fat, isavuconazole Introduction We share our world with fungi. They are ubiquitous in nature; current estimates put the number of fungal species to be as high as 5.1 million [1]. As plentiful as they are, only hundreds of these species are pathogenic to humans, collectively killing more than 1.6 million people annually [2]. Common fungi that cause illness are Aspergillus species, Candida albicans, Cryptococcus neoformans, Blastomyces dermatitidis, and Rhizopus species. The term mucormycosis refers to any fungal infection caused by fungi belonging to the Mucorales order [3].
    [Show full text]
  • Clinical Features of Pulmonary Mucormycosis in Patients with Different Immune Status
    5052 Original Article Clinical features of pulmonary mucormycosis in patients with different immune status Min Peng1#, Hua Meng2#, Yinghao Sun3, Yu Xiao4, Hong Zhang1, Ke Lv2, Baiqiang Cai1 1Division of Pulmonary and Critical Care Medicine, 2Department of Ultrasound, 3Department of Internal Medicine, 4Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China Contributions: (I) Conception and design: M Peng, H Zhang, K Lv; (II) Administrative support: None; (III) Provision of study materials or patients: M Peng, Y Xiao, H Zhang; (IV) Collection and assembly of data: H Meng; Y Sun; (V) Data analysis and interpretation: M Peng, H Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Dr. Hong Zhang; Dr. Ke lv. No.1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. Email: [email protected]; [email protected]. Background: Pulmonary mucormycosis (PM) is a relatively rare but often fatal and rapidly progressive disease. Most studies of PM are case reports or case series with limited numbers of patients, and focus on immunocompromised patients. We investigated the clinical manifestations, imaging features, treatment, and outcomes of patients with PM with a focus on the difference in clinical manifestations between patients with different immune status. Methods: Clinical records, laboratory results, and computed tomography scans of 24 patients with proven or probable PM from January 2005 to December 2018 in Peking Union Medical College Hospital were retrospectively analyzed. Results: Ten female and 14 male patients were included (median age, 43.5 years; range, 13–64 years).
    [Show full text]
  • Concomitant Mucormycosis with Aspergillosis in Patients with Uncontrolled Diabetes
    DOI: 10.7860/JCDR/2021/47912.14507 Case Series Concomitant Mucormycosis with Aspergillosis in Patients with Uncontrolled Diabetes Microbiology Section Microbiology Mellitus: A Case Series ARPANA SINGH1, AROOP MOHANTY2, SHWETA JHA3, PRATIMA GUPTA4, NEELAM KAISTHA5 ABSTRACT Fungal infections are life threatening especially in presence of immunosuppression or uncontrolled diabetes mellitus mainly due to their invasive potential. Mucormycosis of the oculo-rhino-cerebral region is an opportunistic, aggressive, fatal and rapidly spreading infection caused by organisms belonging to Mucorales order and class Zygomycetes. The organisms associated are ubiquitous. Aspergillosis is a common clinical condition caused by the Aspergillus species, most often by Aspergillus fumigatus (A. fumigatus). Both fungi have a predilection for the immunosuppressive conditions, with uncontrolled diabetes and malignancy being the most common among them. Mucormycosis is caused by environmental spores which get access into the body through the lungs and cause various systemic manifestations like rhino-cerebral mucormycosis. Here, a case series of such concomitant infections of Aspergillus and Mucor spp from Rishikesh, Uttarakhand, India is reported. Keywords: Diabetes, Fungal infection, Invasive mycoses, Rhinosinusitis INTRODUCTION Case 2 Mucorales are the universally distributed saprophytes causing A 60-year-old female patient presented with complaints of aggressive and opportunistic infection. They are angio-invasive fever for three days and ptosis for one day. She was a known in nature. Aspergillosis is the clinical condition caused by the case of Type 2 Diabetes Mellitus (T2DM) and hypertension for Aspergillus species most often A. fumigatus [1]. It proves to be the past seven years but was on irregular drug metformin and fatal, if it infects secondarily to the brain.
    [Show full text]
  • A Review of Prolonged Post-COVID-19 Symptoms and Their Implications on Dental Management
    International Journal of Environmental Research and Public Health Review A Review of Prolonged Post-COVID-19 Symptoms and Their Implications on Dental Management Trishnika Chakraborty 1,2 , Rizwana Fathima Jamal 3 , Gopi Battineni 4 , Kavalipurapu Venkata Teja 5 , Carlos Miguel Marto 6,7,8,9 and Gianrico Spagnuolo 10,11,* 1 Department of Conservative Dentistry and Endodontics, Chaudhary Charan Singh University, Meerut, Uttar Pradesh 250001, India; [email protected] 2 Department of Health System Management, Ben-Gurion University of Negev, Beer-Sheva 8410501, Israel 3 Department of Oral and Maxillofacial Surgery, Chettinad Dental College and Research Institute, Kancheepuram, Tamil Nadu 603103, India; [email protected] 4 Telemedicine and Tele Pharmacy Center, School Medicinal and Health Products Sciences, University of Camerino, 62032 Camerino, Italy; [email protected] 5 Department of Conservative Dentistry & Endodontics, Saveetha Dental College & Hospitals, Saveetha Institute of Medical & Technical Sciences, Saveetha University, Chennai, Tamil Nadu 600077, India; [email protected] 6 Faculty of Medicine, Institute of Experimental Pathology, University of Coimbra, 3004-531 Coimbra, Portugal; [email protected] 7 Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Area of Environment Genetics and Oncobiology (CIMAGO), 3000-548 Coimbra, Portugal 8 Centre for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal 9 Clinical Academic Center of Coimbra (CACC), 3004-531 Coimbra, Portugal 10 Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples “Federico II”, 80131 Napoli, Italy Citation: Chakraborty, T.; Jamal, R.F.; 11 Institute of Dentistry, I. M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia Battineni, G.; Teja, K.V.; Marto, C.M.; * Correspondence: [email protected] Spagnuolo, G.
    [Show full text]
  • Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm)
    Editorial | Journal of Gandaki Medical College-Nepal Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm) Reddy KR Professor & Head Microbiology Department Gandaki Medical College & Teaching Hospital, Pokhara, Nepal Medical Mycology, a study of fungal epidemiology, ecology, pathogenesis, diagnosis, prevention and treatment in human beings, is a newly recognized discipline of biomedical sciences, advancing rapidly. Earlier, the fungi were believed to be mere contaminants, commensals or nonpathogenic agents but now these are commonly recognized as medically relevant organisms causing potentially fatal diseases. The discipline of medical mycology attained recognition as an independent medical speciality in the world sciences in 1910 when French dermatologist Journal of Raymond Jacques Adrien Sabouraud (1864 - 1936) published his seminal treatise Les Teignes. This monumental work was a comprehensive account of most of then GANDAKI known dermatophytes, which is still being referred by the mycologists. Thus he MEDICAL referred as the “Father of Medical Mycology”. COLLEGE- has laid down the foundation of the field of Medical Mycology. He has been aptly There are significant developments in treatment modalities of fungal infections NEPAL antifungal agent available. Nystatin was discovered in 1951 and subsequently and we have achieved new prospects. However, till 1950s there was no specific (J-GMC-N) amphotericin B was introduced in 1957 and was sanctioned for treatment of human beings. In the 1970s, the field was dominated by the azole derivatives. J-GMC-N | Volume 10 | Issue 01 developed to treat fungal infections. By the end of the 20th century, the fungi have Now this is the most active field of interest, where potential drugs are being January-June 2017 been reported to be developing drug resistance, especially among yeasts.
    [Show full text]
  • Recent Advances and Novel Approaches in Laboratory-Based Diagnostic Mycology
    Journal of Fungi Review Recent Advances and Novel Approaches in Laboratory-Based Diagnostic Mycology Lewis P. White * and Jessica S. Price Mycology Reference Laboratory, Public Health Wales, Microbiology Cardiff, Cardiff CF14 4XW, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-(0)29-2074-6581 Abstract: What was once just culture and microscopy the field of diagnostic mycology has signifi- cantly advanced in recent years and continues to incorporate novel assays and strategies to meet the changes in clinical demand. The emergence of widespread resistance to antifungal therapy has led to the development of a range of molecular tests that target mutations associated with phenotypic resistance, to complement classical susceptibility testing and initial applications of next-generation sequencing are being described. Lateral flow assays provide rapid results, with simplicity allowing the test to be performed outside specialist centres, potentially as point-of-care tests. Mycology has responded positively to an ever-diversifying patient population by rapidly identifying risk and de- veloping diagnostic strategies to improve patient management. Nowadays, the diagnostic repertoire of the mycology laboratory employs classical, molecular and serological tests and should be keen to embrace diagnostic advancements that can improve diagnosis in this notoriously difficult field. Keywords: mycology; novel targets and applications; next-generation sequencing; advances in serology; advances in molecular diagnostics 1. Introduction Citation: White, L.P.; Price, J.S. The impact of fungal disease is greatly overlooked, but with an ever-increasing im- Recent Advances and Novel munosuppressed or immune-modulated (monoclonal antibody therapies) at-risk popu- Approaches in Laboratory-Based lation, coupled with inevitable exposure to fungi and the availability of more sensitive Diagnostic Mycology.
    [Show full text]
  • Placental Mucormycosis of an IVF-Induced Pregnancy in a Diabetic Patient
    Bahrain Medical Bulletin, Vol. 41, No. 4, December 2019 Placental Mucormycosis of an IVF-Induced Pregnancy in a Diabetic Patient Fatema Juma, MD* Veena Nagaraj, FRCPath** Mooza Rashid, MRCOG*** Abdulla Darwish, FRCPath**** Mucormycosis is a lethal fungal infection, rarely seen in immunocompetent hosts. It has been commonly known to cause aggressive fungal infection in pulmonary and paranasal sinuses. Placental fungal infection caused by Zygomycetes has rarely been described. We present a case of a thirty-year-old pregnant woman with in-vitro fertilization (IVF) twin pregnancy aborted at 16 weeks of gestation due to incidental finding of placental mucormycosis. The patient was treated by evacuation and antifungal treatment. She had uneventful recovery. Bahrain Med Bull 2019; 41(4): 278 - 280 Mucormycosis is an uncommon, rapidly progressive fungal The electrolytes, renal and liver function tests were within infection characterized by large areas of tissue necrosis and normal limits. High vaginal swab culture at 12 weeks was the presence of angio-invasion. It is considered as one of negative. Serology for Hepatitis B and C, HIV and TORCH the infections occurring mainly in immunocompromised screen were negative. individuals and caused by a number of molds classified in the order Mucorales of the class Zygomycetes1-4. Clinical examination revealed a bulky uterus of 14 weeks gestation, the cervix was open and the placenta was seen at Involvement of the lungs and paranasal sinuses are considered cervical os with mild bleeding. She underwent evacuation the most common clinical form of the infection, followed of retained products of conception (ERPCS) under general by rhino-cerebral region, cutaneous, and gastrointestinal anesthesia.
    [Show full text]
  • Hyperbaric Oxygen in the Treatment of Invasive Fungal Infections: a Single-Center Experience
    Original Articles Hyperbaric Oxygen in the Treatment of Invasive Fungal Infections: A Single-Center Experience Eran Segal MD1,2, Monty J. Menhusen DO JD MPH2 and Shawn Simmons MD2 1General Intensive Care Unit, Department of Anesthesiology and Intensive Care, Sheba Medical Center, Tel Hashomer, Israel 2Department of Anesthesia, UIHC, University of Iowa, Iowa, USA Key words: hyperbaric oxygen, mucormycosis, Aspergillus spp., invasive fungal infection Abstract system. Aspergillus is a mold that can cause disease in both Background: Invasive fungal infections by Mucorales or Aspergillus immunocompetent and immunocompromised patients. The most spp. are lethal infections in immune compromised patients. For severe forms of infections with Aspergillus are invasive, which these infections a multimodal approach is required. One potential typically afflict immunocompromised individuals. The pathophysi- tool for treating these infections is hyperbaric oxygen. ology of invasive infections due to the different types of molds is Objectives: To evaluate the clinical course and utility of hyperbaric oxygen in patients with invasive fungal infections by Mucorales or similar in that both groups have a propensity to invade vascular Aspergillus spp. structures and cause necrosis of soft tissue and bone. The out- Methods: We conducted a retrospective chart review of 14 come of invasive fungal infections is very poor. The mortality rate patients treated with HBO as part of their multimodal therapy over of immune compromised patients with either mucormycosis or a 12 year period. Aspergillus infections is reported to be 60–100% [3,4]. Results: Most patients had significant immune suppression due to either drug treatment or their underlying disorder. Thirteen Optimal therapy for these infections requires a multimodal of the 14 underwent surgery as part of the treatment and all were approach with the mainstay being aggressive antifungal drugs receiving antifungal therapy while treated with the hyperbaric combined with extensive surgical debridement.
    [Show full text]
  • Open Letter to Who & Act-A: We Need Affordable
    OPEN LETTER TO WHO & ACT-A: WE NEED AFFORDABLE TREATMENTS FOR THE RISE OF SERIOUS INVASIVE FUNGAL DISEASES THAT ARE LIFE THREATENING FOR COVID-19 SURVIVORS AND HIV+ PEOPLE 23 June 2021 Dear Dr Tedros Adhanom Ghebreyesus, Dr Mariângela Simão, and co-Chairs of the ACT-A Therapeutics Pillar, Dr Phillipe Duneton and Sir Jeremy Farrar, We are writing regarding the urgent need for liposomal amphotericin B (L-AmB) and other drugs for the treatment of severe fungal infections, including the epidemic of mucormycosis (“black fungus”), a Covid-related complication that has claimed the lives to date of more than 10,000 people and resulted in severe disfigurement of many more in India with cases now reported in Nepal. L-AmB is also a crucial treatment for cryptococcal meningitisi, and the long-standing neglected disease, visceral leishmaniasis (kala azar),ii as well as other systemic fungal infectionsiii. Mucormycosis is an otherwise rare, deadly fungal infection that is increasingly affecting Covid-19 patients and survivors in India. According to the government of India, the number of mucormycosis cases increased from 9,000 in late May to 28,252 cases on 7 June 2021. Nepal is also seeing growing numbers of mucormycosis among people with Covid-19.iv We are deeply concerned about the lack of sufficient, predictable, and affordable supply of L- AmB. A high volume of L-AmB vials are needed to treat mucormycosis: 150-300 vials per person.v In India, and perhaps now in Nepal, people are going without treatment or with suboptimal doses. Globally, an estimated 6 million vials of L-AmB are needed to treat today’s cases of cryptococcal meningitis, leishmaniasis (kala azar), and mucormycosis.vi Access to posaconazole (preferably delayed release tablets and injections) is also critical.vii While there are several manufacturers of posaconazole injection and tablets, prices remain high in the private market and governments in affected countries have yet to develop guidelines for mucormycosis and have not made the drug available.
    [Show full text]